SBIR/STTR Research Award
ENDOTHELIN ANTAGONIST
Award amount
$50,000Program and phase
SBIR · Phase IAward year
1989Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- Peptide Technolgies Corp.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
ENDOTHELIN IS A POTENT VASOACTIVE PEPTIDE, RECENTLY DISCOVERED AS THE FORMERLY DESCRIBED ENDOTHELIAL CELL-DERIVED CONTRACTING FACTOR INVOLVED IN THE REGULATION OF VASCULAR TONE. ALTHOUGH ENDOTHELIN POSSESSES POTENT VASOCONSTRICTOR ACTIVITY IN VITRO, ITS ACTIONS IN VIVO APPEAR TO BE COMPLEX. IN THE SYSTEMIC AND RENAL VASCULAR BEDS, VASODILATION SEEMS TO BE THE INITIAL EFFECT. IN THE PULMONARY AND MESENTERIC VASCULAR BEDS, ENDOTHELIN PRODUCES VASOCONSTRICTION. ENDOTHELIN STIMULATES THE GROWTH OF SMOOTH MUSCLE CELLS AND MAY PLAY A ROLE IN ATHEROSCLEROSIS. AN ANTAGONIST OF ENDOTHELIN WILL SERVE TO CHARACTERIZE ITS RECEPTOR INTERACTION AND PHYSIOLOGICAL EFFECTS. ANALOGS WILL BE SYNTHESIZED AND TESTED FOR THE INHIBITION OF ENDOTHELIN ACTIONS ON VASCULAR CONDUCTANCE. A POSSIBLE THERAPEUTIC AGENT FOR ATHEROSCLEROSIS AND HYPERTENSION, AS WELL AS ACUTEINJURY AND SHOCK, MAY THUS BE DEVELOPED.
Technology keywords
Not reported